Kim Hyoung Jung, Kim Kyoung Won, Byun Jae Ho, Won Hyung Jin, Shin Yong Moon, Kim Pyo Nyun, Lee Moo-Song, Lee Moon-Gyu
Department of Radiology, University of Ulsan-Asan Medical Center, 388-1 Pungnap-dong, Songpa-gu, Seoul 138-736, South Korea.
AJR Am J Roentgenol. 2006 Apr;186(4):1059-66. doi: 10.2214/AJR.04.1941.
The purpose of our study was to evaluate the validity of mangafodipir trisodium-enhanced versus ferucarbotran-enhanced MRI in the detection and characterization of hepatic lesions in colorectal cancer patients.
Forty-one patients who were known to have or suspected of having hepatic metastasis from colorectal carcinoma underwent mangafodipir trisodium- or ferucarbotran-enhanced MRI in block randomization methods. Two radiologists independently reviewed the MR images to determine the number of hepatic lesions and to characterize the lesions as malignant or benign. Each lesion was assessed according to its size (small, <or= 2 cm; large, > 2 cm in diameter) on both mangafodipir trisodium- or ferucarbotran-enhanced MRI. The data were correlated with the reference diagnosis: histopathology and intraoperative sonography (n = 16); intraoperative sonography (n = 4); and imaging and clinical diagnosis with follow-up (> 3 months; n = 21). The detection rates and diagnostic accuracies of hepatic lesions on both sets of MR images were assessed using Fisher's exact test.
Eighty-two hepatic lesions (53 metastatic and 29 benign) were identified in 41 patients. No significant differences were seen between mangafodipir trisodium- and ferucarbotran-enhanced MRI for detecting all hepatic lesions (p = 0.183), small hepatic lesions (p = 0.299), all metastases (p = 0.695), and small metastases (p = 0.689). The diagnostic accuracies of mangafodipir trisodium- and ferucarbotran-enhanced MRI showed no significant differences in all hepatic lesions (p = 0.624) and small hepatic lesions (p = 0.641).
Mangafodipir trisodium- and ferucarbotran-enhanced MRI are similar in hepatic lesion detection and characterization in colorectal cancer patients.
我们研究的目的是评估锰福地匹三钠增强磁共振成像（MRI）与羧基麦芽糖铁增强MRI在检测和鉴别结直肠癌患者肝内病变方面的有效性。
41例已知或疑似患有结直肠癌肝转移的患者采用区组随机化方法接受锰福地匹三钠或羧基麦芽糖铁增强MRI检查。两名放射科医生独立审查磁共振图像，以确定肝内病变的数量，并将病变定性为恶性或良性。在锰福地匹三钠或羧基麦芽糖铁增强MRI上，根据每个病变的大小（小，直径≤2 cm；大，直径>2 cm）进行评估。数据与参考诊断相关：组织病理学和术中超声检查（n = 16）；术中超声检查（n = 4）；以及影像学和临床诊断及随访（>3个月；n = 21）。使用Fisher精确检验评估两组磁共振图像上肝内病变的检出率和诊断准确性。
41例患者共发现82个肝内病变（53个转移灶和29个良性病变）。在检测所有肝内病变（p = 0.183）、小肝内病变（p = 0.299）、所有转移灶（p = 0.695）和小转移灶（p = 0.689）方面，锰福地匹三钠增强MRI与羧基麦芽糖铁增强MRI之间未见显著差异。锰福地匹三钠和羧基麦芽糖铁增强MRI的诊断准确性在所有肝内病变（p = 0.624）和小肝内病变（p = 0.641）方面均无显著差异。
在结直肠癌患者肝内病变的检测和鉴别方面，锰福地匹三钠增强MRI和羧基麦芽糖铁增强MRI相似。
